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Abstract 
The aetiology of mental retardation and dysmorphism is 
still poorly understood in over half of the affected individuals. 
Recent studies have shown that genomic mutations such as Copy 
Number Variants (CNV) can be important factors predisposing to 
the highly heterogeneous clinical conditions observed in affected 
individuals. Genome−wide array−Comparative Genomic 
Hybridization  (aCGH) is the best technology available so far for a 
first  screening of  CNVs in genomic DNA in patients and control 
individuals. However, CNVs detected by aCGH need validation by 
an independent method such as Multiplex Ligation-dependent 
Probe Amplification (MLPA). In this report we present the results 
of a MLPA analysis performed on 120  mentally retarded patients 
and their parents  and 400 samples from a reference population. 
Patients who underwent MLPA were previously scored positive to 
aCGH.  
Our results show that, overall, from the 150 CNVs identified by 
aCGH, 123 were confirmed by our MLPA analysis and overall 
account for 65 gains (size range: from 3,6 Kb to 3,0 Mb) and 58 
losses (size range: from 2,2 Kb to 1,9 Mb).  At least 16 CNVs are 
de novo (11 loss, 5 gain). Inheritance from a healthy parent  could 
be established only for 83 CNVs. For 24 CNVs it was not possible 
to establish if they were de novo or inherited because one or both 
parents were unavailable for the analysis. In the majority of cases, 
a given CNV appear to be unique to a particular patient as far 
their chromosomal location and size is concerned. In contrast five 
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CNVs  are shared each by two  patients. One CNV_loss in 
chromosome 15q11.2 was shared by six unrelated patients.  
To investigate on the possible pathogenic role played by 
CNVs in this phenotypically and genetically heterogeneous  
population of mentally retarded patients and thus select the 
strongest candidate CNVs we  have applied a multi-step strategy.  
Briefly, we first excluded CNVs also occurring in the general 
population. To this end, we screened by MLPA 400 neurotypical 
geographically- and ethnically-matched individuals. Second only 
CNVs occurring as de novo events were considered. Third, we 
queried  a large body of data stored in the literature and in several 
databases to exclude CNVs previously associated to mental 
retardation (MR) or described as phenotypically unexpressed 
polymorphisms in the general population. The best candidate 
CNVs  selected as just described were then analyzed for their 
gene content and to assess by in silico functional annotation 
analysis the role of these genes in nervous system.  This 
approach led in some cases to the identification of several CNV, 
genes and statistically significant ontologies related to nervous 
system thus supporting their pathogenic role. A result of special 
interest was the identification in one MR patient with a complex 
phenotype of a duplicated microRNA (hsa-miR-150) overlapping a 
CNV  on chromosome 19. The functions and diseases associated 
to the  individual target genes/mRNA regulated by this microRNA 
appear to be highly correlated to the clinical phenotypes displayed 
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by this patient and suggest the occurrence of a new MR 
syndrome caused by a duplicated microRNA.   
 In summary, the results of our study: (i) emphasize the 
importance of MLPA to exclude false positives generated by 
aCGH, (ii) describe the identification of  novel  CNVs and genes 
potentially implicated in MR. We believe that the results of this 
study will significantly contribute to the discovery of new 
microdeletion syndromes and a more precise correlation of the 
mutant genotype with the highly variable phenotype displayed by 
mentally retarded patients.    
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Introduction 
Mental retardation (MR) or developmental delay is a 
pervasive condition, mainly defined  as an incomplete or arrested 
development of the mind and often associated with malformations 
or multiple congenital anomalies and/or dysmorphic features, 
which is estimated to affect 2–3% of the population (1), thus 
representing highest socioeconomic costs in developed societies 
(2). From a genetic  point of view, MR can be considered as a 
complex disorder with an extremely high degree of genetic 
heterogeneity highlighted by the evidence that the underlying 
known defects span from single point mutation to large deletion or 
duplication at thousand of different loci. 
The search for the genes involved in mental retardation is 
hampered by an extremely high degree of genetic and phenotypic 
heterogeneity and by the fact that most of these disorders occur 
sporadically in the population, mainly because the de novo nature 
of the mutations and because affected patients will seldom have 
offspring. It is not surprising that the majority of loci found to be 
associated with MR have been identified in X-linked conditions 
because of their characteristic inheritance patterns. Many other  
loci for MR have  been mapped to autosomes  by classical gene 
mapping, but despite these large efforts roughly 40-50 % of the 
genetic causes of MR still remains unknown. Given this 
background, whole genome scan methods, such as karyotype 
analysis, have been successfully used to investigate the MR and 
until now cytogenetic imbalances are the most frequently 
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identified causes of MR. More recently, a new high resolution 
whole- genome scan method called Array-CGH (comparative 
genomic hybridization) (3) has been implemented. Since its 
introduction in MR research, Array-CGH has proven to be a 
powerful and promising method that is revolutionizing cytogenetic 
diagnosis, at least doubling the detection rate of  MR loci [4]. 
While highlighting many formerly unresolved cases, the array-
CGH demonstrated the high degree of variability in Human 
genome in term of structural variation. It is now recognized that 
the genomes of any two individuals in the human population differ 
from one another with respect to the copy number of thousands 
[5]. As many of these structural variations, called CNVs could 
potentially represent risk factors, and some of them have already 
been linked to human diseases, they will have a great impact into 
the study of the genetic basis of complex diseases. On the other 
hand, such a complexity becomes a challenge for the 
cytogeneticist when interpreting array-CGH results performed in 
clinical diagnostic settings because there isn't yet a confident 
background about the biological significance for many of the 
CNVs [6]. In respect to MR,  classification into benign or 
pathogenic CNVs greatly depends on whether they have been 
found in normal individuals or identified in patients as a de novo 
events. This information is thus crucial both for a correct 
diagnosis and for the understanding of the role of the genes 
involved.  
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A critical aspect of aCGH is that it requires confirmation of 
CNVs by an independent method such as Multiplex ligation-
dependent probe amplification (MLPA) [7]. MLPA is a new 
technique suitable for measuring sequence dosage, allowing 
large number of samples to be processed simultaneously, thus 
reducing significantly laboratory work. In this study we have used 
MLPA to re-assess a large sample of MR patients previously 
tested by aCGH. 
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Materials and methods 
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Patients 
DNA samples  
From initial aCGH screening of 1200 patients (see above) 150 
CNVs borne by 120 patients were selected after the exclusion of: 
(i)  CNVs also reported in the Database of Genomic Variants 
(http://projects.tcag.ca/variation) (general population) and (ii) 
CNVs described as pathogenic according to the literature.  We 
have also used 400 DNA samples from ethnically/geographically-
matched subjects recruited among the healthy volunteer blood 
donors.  
 
MLPA analysis  
Principle of the method and main analytical steps   
Multiplex Ligation-Dependent Probe Amplification (MLPA) is an 
application that can be used for the detection of multiple 
chromosomal aberrations consisting of gene and genomic dosage 
variations such as Copy Number Variants. The main steps of this 
procedure are summarized hereafter (figure 1): 
1. DNA sample is heated so that it denatures. The MLPA 
probes, each consisting of two oligonucleotides, hybridize 
to the sample DNA.  
2. When two oligonucleotides of each probe are hybridized to 
their target sequence, they are connected by enzymatic 
ligation to form one complete probe.  
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3.  During the PCR reaction, only complete probes are 
amplified exponentially  
4. Amplification products are separated and quantified using 
ABI3130 capillary electrophoresis and Gene Mapper 
software (Applied Biosystems). 
 
Designing synthetic MLPA probes  
MLPA probes (fugure 2) consist of two oligonucleotides: the Left 
Probe Oligonucleotide (LPO) and the Right Probe Oligonucleotide 
(RPO) (Figure 2, part 7 and 8). Each oligonucleotide in turn 
usually contains 2 parts. The LPO contains the recognition 
sequence of the Forward PCR primer at its 5’ end (part 1) and the 
left hybridizing sequence (LHS) at its 3’ end (part 3). The RPO 
contains a right hybridizing sequence (RHS, part 4) at its 5’ end 
and the sequence recognized by the reverse primer at its 3’end 
(part 6). The primer sequences are used in the amplification of the 
probe during the PCR reaction. 
For the analysis of CNV detected in mentally retarded 
patients and controls, the MLPA probes were designed and built 
for each selected CNV. Two-four probes per locus were designed 
according to the protocol available at MRC Holland website 
(http://www.mrc−holland.com/pages/indexpag.html). For each 
CNV two probes were designed near the internal CNV 
boundaries, based on aCGH results. A Blast 
http://genome.ucsc.edu/cgi-bin/hgGateway) analysis was instead 
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used to ensure that probes hybridize to the suitable genomic 
regions. For every multiplex reaction, probes for three control loci 
known to be represented only once per haploid genome, was 
added in the multiplex reaction.  
 
Statistical  analysis of the electropherogram-related  data  
In order to efficiently process MLPA data, a spreadsheet was 
generated in Microsoft Excel. First, data corresponding to each 
sample (patient and control DNA) were normalized by dividing 
each probe signal’s strength value (the area of each peak) by the 
average signal strength of 10 control probes to generate for each 
peak a Relative Peak Area (RPA). The RPA for each probe in a 
patient sample was then compared to the RPA obtained from a 
control sample by dividing the patient RPA by the control RPA for 
each peak. This value was then used to define the following 
categories according to Calì et al. [8]: (i) "normal" for values in the 
range 0.75-1.25 (these values correspond to more than three 
standard deviations above and below the mean of the normalized 
data); (ii) "deleted" for values smaller than 0.60, and (iii) 
"duplicated" for values larger than 1.40 (these values correspond 
to more than five standard deviations above and below the mean 
of the normalized data). As a quality test for the probes, we 
computed the standard deviation (SD) of the normalized signals 
for the ten control probes for both patients and control individuals. 
MLPA analysis was repeated for samples yielding a SD value 
exceeding the threshold value of σt = 0.05. This value 
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corresponds approximately to the mean value of the standard 
deviations of the normalized data relative to the ten control probes 
for all individuals (both patients and control).   
 
In silico analyses 
We referred to several international databases which collect 
information on CNVs and overlapping genes:  
 Database of Genomic Variants 
(http://projects.tcag.ca/variation) 
 PubMed (http://www.ncbi.nlm.nih.gov/pubmed)  
 OMIM (http://www.ncbi.nlm.nih.gov/omim/)  
 Entrez Gene (http://www.ncbi.nlm.nih.gov/gene/)  
For statistical functional annotation analyses the following 
databases and implemented software were used:  
 Ingenuity Pathways Analysis (IPA) 
http://www.ingenuity.com/products/analysis_services.html 
 Gene Ontology (GO) http://www.geneontology.org/ 
Mapping of microRNA in CNVs was achieved using the UCSC 
Genome Browser (http://genome.ucsc.edu/) using the Build 36 
version of the human genome. Genes targeted by microRNAs 
and ontologies and diseases associated to the targeted genes 
were identified using the miR-Ontology Database 
(http://ferrolab.dmi.unict.it/miro/). 
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Results and Discussion 
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General features of CNVs confirmed by MLPA 
Overall, the 123 selected CNVs  consist  of 65  gains 
(ranging from 3,6 Kb to 3,0 Mb) and 58 losses (ranging from 2,2 
Kb to 1,9 Mb). 11 CNVs are gene deserts, i.e., containing  no 
genes. The chromosomal location of these CNVs are shown in  
Figure 3. 16 CNVs are de novo (11 losses and 5 gains) (see 
Figure 4).  83 CNVs are inherited from a healthy parent, whereas 
for 24 CNVs it was not possible to establish if they were de novo 
or inherited because one or both parents were unavailable for the 
analysis. In many instances, a given CNV resulted specific to a 
given patient, whereas each of 5 CNVs was shared by two 
unrelated patients, and only 1 CNV resulted shared by six 
unrelated patients (see figure 5).  
 What can we say about the pathogenic role of these 
CNVs? A first important consideration concerns the phenotypic 
heterogeneity of the patients we have studied by aCGH/MLPA. 
Indeed, beside the intellectual deficit that is present  in all patients 
(though the IQ appeared significantly variable across the 
subjects), the population of MR individuals that we have studied 
displays other phenotypes and endophenotypes that are only 
present in subgroups of patients. These latter phenotypes include: 
behavioral disturbances, epilepsy and EEG anomalies, 
dysmorphisms just to mention few relevant items.  Then, a priori 
one expects a wide spectrum of etiological factors (genetic, 
environmental) to be potentially involved in the expression of 
these phenotypes and the variable degree of MR also not 
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necessarily involving the CNV borne by the patient.  Consistent 
with this prediction, our results show that not only very few 
patients share the same deleted/duplicated genomic region and 
genes, also the analysis of biofunctions performed using Gene 
Ontology (GO) (results not shown) on all genes overlapping all 
CNVs detected in all MR patients did not yield statistically 
significant GO terms (no gene enrichment). In other words overall 
the genes overlapping CNVs appear to be associated to a wide 
range of biological processes and molecular functions. Another 
problematic aspect of this study concerns the assessment of the 
pathogenic role of the inherited CNVs for which no phenotype is 
seen in the parents. Consequently, the genes overlapping the de 
novo CNVs represent a set of more promising candidates for their 
involvement  in MR. A strong argument in favour of the potential 
pathogenic role of the CNVs detected in MR patients we have 
studied is provided by the observation that about 65 % of the 123 
CNVs were not found in an ethnically/geographically-matched 
population of 400 neurotypical individuals also analyzed by us 
with MLPA in this study.  Another consideration concerns the 
number of genes involved in a CNV. Generally speaking,  a larger 
number of genes duplicated or deleted suggest a higher chance 
of a pathogenic role for a given CNV. However, in this case it is 
difficult to say whether all genes in that CNV contribute to the 
expression of the phenotype. In contrast, for CNVs involving one 
(or very few) gene it should be easier to call that gene as a 
candidate for MR in a particular patient.   Finally, a recurrent CNV 
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among some MR patients (we have found several cases of this 
type in our study, see above) was also taken into account in our 
evaluation of the potential pathogenic role of CNVs.  
All the above considerations were translated in an algorithm that 
we have used to select the best candidates among the many CNV 
identified in patients (see flowchart in fig. 6).  
 
A recurrent CNV  on chromosome 15q11.2  
The only CNV shared by six patients consists of  a deletion 
on chromosome 15q11.2 whose size ranges  from 20,307,869 bp 
to 20,773,190 bp removing the TUBGCP5, NIPA1, NIPA2, and 
CYFIP1 genes (see figure 5). This deletion partly overlaps the 
Prader–Willi/Angelman (PWS/AS) syndrome region in all six 
patients, but the deleted patients do not display the phenotypic 
traits typical of PWS/AS. This deletion  has been  already 
described in nine MR patients who also share with our patients 
several clinical features, including delayed motor and speech 
development, dysmorphisms and behavioural problems (ADHD, 
autism, obsessive–compulsive behaviour) [9] (see Table 1 for a 
summary the clinical features present in the six patients).  
This deletion was not found in 400 normal individuals 
tested by us with MLPA and by the 350 controls tested (see 
Figure 7) in the study of Doornbos et al. [9]. Another interesting 
finding was that all six patients also share astigmatism, a sign that 
was not reported in the study of Doornbos et al. [9]. This latter 
discrepancy between the two studies may be simply explained by 
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the fact that in the study of Doornbos et al. [9] astigmatism was 
not evaluated. The four genes overlapping the deletion on 
chromosome 15q11.2 are: TUBGCP5, NIPA1, NIPA2, and 
CYFIP1 genes. Below we report a brief description on the function 
of and other information (knockout mouse model) on these genes 
in relation to the clinical phenotype seen in the six patients.  
TUBGCP5 (Tubulin complex-associated protein 5), or GCP5, is a 
gene that contains 23 exons and spans 46.8 kb. The gene is 
ubiquitously expressed, but the highest expression is found in the 
subthalamic nuclei of the brain (KIAA1899 in Nagase et al. [10]). 
These nuclei are involved in ADHD and obsessive–compulsive 
behaviour [11]. The  deletion of this gene could thus explain not 
only the behavioural  problems seen in our patients, but also the 
more severely affected  behaviour associated to Prader–Willi 
syndrome patients with a type I deletion that overlaps the deletion 
that we have found in the six patients. No knockout mouse is 
currently available. NIPA1 is the ‘‘Nonimprinted gene in PWS/AS 
chromosome region  1’’; it contains 5 exons and spans 41.1 kb. 
This gene is highly  expressed in neuronal tissue and encodes a 
putative membrane  transporter, most likely involved in 
intracellular magnesium  transport. Gain-of-function mutations are 
described in patients  with spastic paraplegia type 6 [12, 13]. No 
knockout mouse is currently available. The  NIPA2 gene contains 
7 exons and  spans 29 kb; it encodes a membrane transport 
protein that plays  a role in renal magnesium metabolism [14]. 
There is no further  information about the function of this gene or 
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the encoded protein [15].  No knockout mouse is currently 
available. Finally, the CYFIP1 gene, ‘‘Cytoplasmic FMRP 
interacting protein 1’’, contains  1253 amino acids and is a 
member of a highly conserved protein  family. CYFIP1 interacts 
with FMRP (fragile X mental retardation  protein) and GTPase 
RAC1, a small GTP-binding protein that is  involved in the 
development and maintenance of neuronal structures.  CYFIP1 is 
present in synaptosomal extracts, indicating co-localisation  with 
FMRP and RAC1 in dendritic fine structures [15, 16].  Related to 
CYFIP1 gene, a model knock-out mice, has been studied by 
Nishimura et al. [17]. Authors identified a potential molecular link 
between FMR1-FM and dup(15q), the cytoplasmic FMR1 
interacting protein 1 (CYFIP1), which was up-regulated in 
dup(15q) patients.  Authors also confirmed this link in vitro by 
showing common regulation of two other dysregulated genes, 
JAKMIP1 and GPR155, downstream of FMR1 or CYFIP1 and 
confirmed the reduction of the Jakmip1 protein in Fmr1 knock-out 
mice, demonstrating in vivo relevance.  
Based on the roles that NIPA1 and CYFIP1 have  in cell 
processes, it can be hypothesised that they are important in 
neurodevelopment, and thus their haploinsufficiency might play a 
role in the motor and speech delays seen in all six of our patients. 
None of the four genes involved in this microdeletion are known  
to undergo imprinting. 
 A clear statement on the pathogenic role of this deletion in 
our patients as well in the patients studied by Dombos et al., [9] is 
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not possible at this time due to the fact that the latter Authors 
describe in their study that in some cases the deletion is 
transmitted to the children from unaffected parents. However, it 
can be hypothesized that  other modififier loci may be required 
together with this deletion to express the abnormal phenotypes 
observed in all these patients. Thus, further studies are required  
to establish the existence of a novel microdeletion syndrome 
possibly linked to this CNV of 15q11.2.  
 
Three de novo CNVs each borne by a different patient containing 
only 1 gene 
Each of three (FBXO11, SOX5 and  EHBP1) genes were 
present in three de novo CNVs detected in 3 patients 
respectively. We investigated further on these three genes 
because they comply with most stringent selection criteria 
(described above). Detailed information on their function is 
reported below.   
SOX5 (Transcription factor SOX-5) 
 
Member Of: Sox 
Entrez Gene 
Name: 
SRY (sex determining region Y)-box 5 
Synonym(s): 
A730017D01RIK, AI528773, LOC312831, L-SOX5, 
MGC124352, MGC35153, Sox5 
Source Id: -- 
Protein Family, 
Domain: 
DNA binding, HMG box, protein heterodimerization, 
transcription factor, transcription regulator 
Subcellular 
Location: 
Nucleus 
Canonical 
Pathway: 
Wnt/β-catenin Signaling 
microRNA: MIR125B1, MIR125B2, MIR15A (includes 
EG:406948), MIR224 (includes EG:407009), MIR34A 
(includes EG:407040) 
 
 20 
Top Findings from Ingenuity Knowledge Base (show all 166 categorized 
literature Findings) 
regulates: COL2A1, BMP6, ACAN, RUNX2, HSPG2 (includes EG:3339), 
FGFR3, Cbp/p300 
regulated by: NFkB, HRAS, EDN1, ABL1, BCR, IL3, retinoic acid, SOX9, 
SCXA, Wnt, RUNX1, RUNX2, BRD2, RAC1, CDC42 
binds: SOX6, SOX5 (includes EG:6660), SMAD7, SMAD1, SMAD5, 
Cbp/p300, MIR224 (includes EG:407009), MIR125B1, MIR15A 
(includes EG:406948), MIR125B2, MIR34A (includes 
EG:407040), LIPE, FGF3 
role in cell: commitment, apoptosis, development 
disease: rheumatoid arthritis, Parkinson's disease, acquired 
immunodeficiency syndrome, ischemic stroke, coronary artery 
disease, non-insulin-dependent diabetes mellitus, insulin-
dependent diabetes mellitus, hypertension, Crohn's disease, 
bipolar disorder, schizophrenia 
Descriptions from External Databases 
Entrez Gene 
Summary: 
This gene encodes a member of the SOX (SRY-related HMG-
box) family of transcription factors involved in the regulation 
of embryonic development and in the determination of 
the cell fate. The encoded protein may act as a 
transcriptional regulator after forming a protein complex with 
other proteins. The encoded protein may play a role in 
chondrogenesis. A pseudogene of this gene is located on 
chromosome 8. Multiple transcript variants encoding distinct 
isoforms have been identified for this gene. [provided by 
RefSeq] 
GO Annotations 
Molecular 
Function: 
transcription factor activity; protein binding; promoter 
binding; protein heterodimerization activity 
Biological 
Process: 
in utero embryonic development; transcription from RNA 
polymerase II promoter; central nervous system neuron 
differentiation; cell fate commitment; regulation of 
transcription; negative regulation of transcription, DNA-
dependent; positive regulation of transcription from RNA 
polymerase II promoter; oligodendrocyte differentiation; 
cartilage development; regulation of timing of neuron 
differentiation 
Cellular 
Component: 
nucleus 
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FBXO11 F-box only protein 11 
ntrez Gene 
Name: 
F-box protein 11 
Synonym(s): 
C80048, FBX11, FLJ12673, JF, MGC156416, MGC44383, 
PRMT9, UBR6, UG063H01, VIT1 
Source Id: -- 
Protein Family, 
Domain: 
enzyme, F-box domain, histone-arginine N-methyltransferase, 
protein binding, zinc finger domain 
Subcellular 
Location: 
Unknown 
Canonical 
Pathway: 
-- 
microRNA: MIR124-1 (includes EG:406907), MIR124-2 (includes 
EG:406908), MIR124-3 (includes EG:406909), MIR129-1 
(includes EG:406917), MIR129-2 (includes 
EG:406918), MIR184 (includes 
EG:406960), MIR199A1, MIR199A2, MIR204 (includes 
EG:406987), MIR24-1 (includes EG:407012), MIR294 
(includes EG:100049712), MIR298 (includes 
EG:723832), MIR325 (includes EG:100313970), MIR339 
(includes EG:100314146), MIR34A (includes 
EG:407040), MIR34C (includes EG:407042) 
Top Findings from Ingenuity Knowledge Base (show all 38 categorized 
literature Findings) 
regulates: -- 
regulated by: -- 
binds: SKP1, CUL1, COPS5, COPS6, RBX1 (includes EG:9978), TXN, 
EFHD1, HSPE1, GXYLT1, MIF, GDI1, PSMA6, TP53, TKT, 
MIR339 (includes EG:100314146) 
role in cell: -- 
disease: -- 
Descriptions from External Databases 
Entrez Gene 
Summary: 
This gene encodes a member of the F-box protein family which 
is characterized by an approximately 40 amino acid motif, the 
F-box. The F-box proteins constitute one of the four subunits 
of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-
box), which function in phosphorylation-dependent 
ubiquitination. The F-box proteins are divided into 3 classes: 
Fbws containing WD-40 domains, Fbls containing leucine-rich 
repeats, and Fbxs containing either different protein-protein 
interaction modules or no recognizable motifs. The protein 
encoded by this gene belongs to the Fbxs class. It can function 
as an arginine methyltransferase that symmetrically 
dimethylates arginine residues, and it acts as an adaptor 
protein to mediate the neddylation of p53, which leads to the 
suppression of p53 function. This gene is known to be down-
regulated in melanocytes from patients with vitiligo, a skin 
disorder that results in depigmentation. Polymorphisms in this 
gene are associated with chronic otitis media with effusion and 
recurrent otitis media (COME/ROM), a hearing loss disorder, 
and the knockout of the homologous mouse gene results in 
the deaf mouse mutant Jeff (Jf), a single gene model of otitis 
media. Alternatively spliced transcript variants encoding 
distinct isoforms have been identified for this gene. [provided 
by RefSeq] 
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GO Annotations 
Molecular 
Function: 
ubiquitin-protein ligase activity; protein binding; zinc ion 
binding; protein-arginine N-methyltransferase activity; metal 
ion binding 
Biological 
Process: 
protein modification process; ubiquitin-dependent protein 
catabolic process; protein ubiquitination 
Cellular 
Component: 
ubiquitin ligase complex; nucleus; cytoplasm 
 
 
EHBP1 (EH domain-binding protein 1) 
Entrez Gene 
Name: 
F-box protein 11 
Synonym(s): 
C80048, FBX11, FLJ12673, JF, MGC156416, MGC44383, 
PRMT9, UBR6, UG063H01, VIT1 
Source Id: -- 
Protein Family, 
Domain: 
enzyme, F-box domain, histone-arginine N-methyltransferase, 
protein binding, zinc finger domain 
Subcellular 
Location: 
Unknown 
Canonical 
Pathway: 
-- 
microRNA: MIR124-1 (includes EG:406907), MIR124-2 (includes 
EG:406908), MIR124-3 (includes EG:406909), MIR129-1 
(includes EG:406917), MIR129-2 (includes 
EG:406918), MIR184 (includes 
EG:406960), MIR199A1, MIR199A2, MIR204 (includes 
EG:406987), MIR24-1 (includes EG:407012), MIR294 
(includes EG:100049712), MIR298 (includes 
EG:723832), MIR325 (includes EG:100313970), MIR339 
(includes EG:100314146), MIR34A (includes 
EG:407040), MIR34C (includes EG:407042) 
Top Findings from Ingenuity Knowledge Base (show all 38 categorized 
literature Findings) 
regulates: -- 
regulated by: -- 
binds: SKP1, CUL1, COPS5, COPS6, RBX1 (includes EG:9978), TXN, 
EFHD1, HSPE1, GXYLT1, MIF, GDI1, PSMA6, TP53, TKT, 
MIR339 (includes EG:100314146) 
role in cell: -- 
disease: -- 
Descriptions from External Databases 
Entrez Gene 
Summary: 
This gene encodes a member of the F-box protein family which 
is characterized by an approximately 40 amino acid motif, the 
F-box. The F-box proteins constitute one of the four subunits 
of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-
box), which function in phosphorylation-dependent 
ubiquitination. The F-box proteins are divided into 3 classes: 
Fbws containing WD-40 domains, Fbls containing leucine-rich 
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repeats, and Fbxs containing either different protein-protein 
interaction modules or no recognizable motifs. The protein 
encoded by this gene belongs to the Fbxs class. It can function 
as an arginine methyltransferase that symmetrically 
dimethylates arginine residues, and it acts as an adaptor 
protein to mediate the neddylation of p53, which leads to the 
suppression of p53 function. This gene is known to be down-
regulated in melanocytes from patients with vitiligo, a skin 
disorder that results in depigmentation. Polymorphisms in this 
gene are associated with chronic otitis media with effusion and 
recurrent otitis media (COME/ROM), a hearing loss disorder, 
and the knockout of the homologous mouse gene results in 
the deaf mouse mutant Jeff (Jf), a single gene model of otitis 
media. Alternatively spliced transcript variants encoding 
distinct isoforms have been identified for this gene. [provided 
by RefSeq] 
GO Annotations 
Molecular 
Function: 
ubiquitin-protein ligase activity; protein binding; zinc ion 
binding; protein-arginine N-methyltransferase activity; metal 
ion binding 
Biological 
Process: 
protein modification process; ubiquitin-dependent protein 
catabolic process; protein ubiquitination 
Cellular 
Component: 
ubiquitin ligase complex; nucleus; cytoplasm 
 
Though based on our selection strategy all three genes have 
passed several selection steps suggesting they would be good 
candidates for MR, the most compelling support based on the 
available information in the literature and databases (summarized 
above) is for SOX65. 
 
One microRNA (hsa-miR-150) overlaps a CNV_gain on 
chromosome 19 borne by one RM patient  
miRNAs are small non-coding RNA molecules that regulate 
the translation of target mRNAs. Binding of miRNAs to target 
mRNAs results in translational arrest and, in some instances, 
transcript degradation. At least 1000 miRNAs have been identified 
in the human genome, and most of them have their genes in the 
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non-coding regions. Of all human whole genome mRNAs, 
approximately one-third are predicted to be miRNA targets by 
bioinformatics analysis. These non coding RNAs  can 
simultaneously control post-transcriptionally the expression levels 
of hundreds of genes 
miRNAs have key roles in diverse physiological processes, 
including nervous system development and function and the 
evidences that they are involved in disease etiology are steadily 
increasing.  
Abnormal variation of the  expression levels of a microRNA  may 
deregulates  the  synthesis of the many proteins encoded by its 
mRNA targets . Thus, because a microRNA embedded in a CNV 
is expected to lead to increased repression (CNV gain) or 
upregulation (CNV loss) of its mRNA targets, we have screened  
CNVs detected in MR patients to look for overlapping microRNAs. 
Interestingly, using  an in silico approach we  have found that 
patient # 03177 bears a de novo CNV_gain on chromosome  
19q13.33 overlapping the hsa-miR-150 microRNA. The duplicated 
genomic region  also overlaps 40 coding genes listed below: 
FUT1, FGF21, BCAT2, HSD17B14, PLEKHA4, PPP1R15A, 
TULP2, NUCB1, DHDH, BAX, FTL, GYS1, RUVBL2, LHB, CGB, 
SNAR-G2, CGB2, CGB1, SNAR-G1, CGB5, CGB8, CGB7, NTF4, 
KCNA7, SNRNP70, LIN7B, C19orf73, PPFIA3, HRC, TRPM4, 
SLC6A16, CD37, TEAD2, DKKL1, CCDC155, PTH2, SLC17A7, 
PIH1D1, ALDH16A1, FLT3LG, RPL13. 
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 We have also queried several microRNA databases (Targetscan, 
miRanda, PicTar) to identify which mRNA targets are regulated by 
hsa-miR-150. Only mRNA identified as targets in all three 
databases were considered. By this procedure we selected 15 
mRNAs  predicted to be regulated by this microRNA, (listed 
below): CACNA1G, CALCR,  COL4A4, EGR2, FOXO4, FZD4, 
GABRG2, GLDC, GLP1R, NOTCH3, PAFAH1B1, PAK1, 
PPARGC1A, RAD23B, SLC2A4. 
An  IPA analysis was then performed to uncover possible 
associations between the (i) coding genes overlapping this CNV 
or (ii) the mRNAs/protein targets for the hsa-miR-150 from one 
side  and the biofunctions related to nervous system development 
and function from the other side.  Many  statistically significant 
neurofunctions were identified. In Table 2 we list a selection of the 
statistically significant IPA ontologies associated to the genes 
regulated by the has-miR-150  
 
Correlation of genotype (genes in CNV) to the clinical phenotype 
in patient # 03177 
Patient # 03177 has a complex phenotype  that can be 
summarized in the following list of clinical signs:   
Mental retardation (mild), Chiari malformations type I and  
syringomyelia, white-matter abnormalities, (hypodensity), cerebral 
edema,  partial epilepsy, paroxysmal manifestations, episodes of 
crisis, psychosis, familial  headache, delayed psychomotor 
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development, hypotonia, dorsal-lumbar scoliosis, hearing 
disorder, sleep disorder.     
 
It is interesting to note that several genes regulated by has-miR-
150 have been individually implicated in previous studies in    
clinical phenotypes that overlaps those present  in this patient 
[i.e., PAFAH1B1 and PPARGC1A in schizophrenia (psychotic 
manifestations are present in our patient), GABRG2  CACNA1G 
in epilepsy,  FZD4 in deafness (mouse), NOTCH3 an CALCR in 
migraine, PAFAH1B1 FGF2R (the receptor for FGF2) in Chiari 
syndrome type I (see Box below for details)]. 
Looaking at the many functions (see Table 2) played the genes 
regulated by has-miR-150  in the morphogenesis of neurons, 
nervous tissue and  CNS as well as in bone and connective tissue 
morphogenesis  it is tempting to speculate that  dosage variation 
in this single miRNA at one or more critical developmental stages 
would be  largely responsible for the spectrum of phenotypic 
manifestations displayed by patient # 03177 especially mental 
retardation, epilepsy, Chiari syndrome, migraine. We also need to 
emphasize  that  certain genes (e.g., EGR2) among those 
regulated by the miRNA appear to  act pleiotropically on multiple  
cellular pathways, in different cell types and tissues as well as in 
concert with the other genes regulated by the same miRNA.       
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____________________________________________________ 
What are the Chiari malformations? a sketch on phenotypic  and 
biological aspects  
___________________________________________________ 
 Chiari malformations (CMs) are structural defects in the cerebellum. If 
there is an occipital bone hypoplasia with foramen magnum obstruction 
at the lower rear of the skull , the cerebellum and brainstem can be 
pushed downward to form the so-called cerebellar tonsils through the 
foramen magnum. The resulting pressure on the cerebellum can block 
the flow of cerebrospinal fluid (the liquid that surrounds and protects the 
brain and spinal cord) thus giving rise to syringomyelia. This condition  
can cause a range of symptoms including dizziness, muscle weakness, 
numbness, vision problems, headache, and problems with balance and 
coordination. There are three primary types of CM. The most common 
is Type I, which may not cause symptoms and is often found by 
accident during an examination for another condition.   
As far the embryological cause of this condition is concerned it has 
been postulated that the etiology of CM1 involves underdevelopment of 
the occipital bone, perhaps due to abnormal development of the 
occipital somite originating from the paraxial mesoderm, resulting in 
overcrowding in the posterior fossa. In other words,  current findings 
suggest  that the bony components of the posterior fossa are not fully 
developed in these patients, supporting the concept that CM1 is a 
disorder of the paraxial mesoderm 
It is  hypothesized that genetic factors play a role in the etiology of 
abnormalities of these hindbrain structures. 
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It is noteworthy that certain genes regulated by the miRNA and 
several statistically significant IPA terms associated to these 
genes are involved in the morphogenesis of bone and cerebellum 
namely (taken from Table 2): 
 purkinje cell degeneration  (CACNA1G)  
 ossification of bone  (CALCR, EGR2)  
 developmental process of bone (CALCR, GR2, GLP1R) 
 resorption of bone (CALCR, GLP1R)   
 development of rhombomere 3 (EGR2)  
 development of rhombomere 5 (EGR2)   
 development of rhombomere 6 (EGR2) 
 degeneration of cerebellum (FZD4) 
 
Conclusions 
In summary, the results of our study show that MLPA is a 
valid and efficient (large number of samples can be processed 
simultaneously) method for the evaluation of cryptic genomic 
imbalances detected by array−CGH in mental retardation and 
other disorders. Although the molecular bases of mental 
retardation still remain largely unknown our study has generated a 
set of novel candidates CNVs and genes etiologically linked to 
MR. Confirmation of the potential pathogenic role of such CNVs 
and genes shall await the description of other MR patients 
bearing the same genomic imbalances and phenotypes.  Such 
reverse phenotyping approach shall be increasingly effective in 
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the near future thanks to the increased use of high throughput   
technologies such as whole-genome aCGH and next-generation 
sequencing. As a result of special interest from this thesis there is 
the likely identification  of a novel microduplication   syndrome in a 
MR patient with a complex phenotype involving a microRNA 
overlapping a CNV of chromosome 19. 
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Figures 
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Figure1: MLPA technique 
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Figure 2: MLPA probe terminology 
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Figure 3: Chromosomal positions of Copy Number Variants 
identified by aCGH and MLPA in 120 mentally retarded patients 
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Figure 4: De novo CNVs identified in this study 
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 Figure 5: CNV in 15q11.2 region shared by six unrelated MR 
patients  
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Figure 6: Algorithm used to select the best candidates genes  
150 CNVs
1200 Italian mental retardation patients
screening Array-CGH
123 CNVs confirmed
MLPA validation
27 CNV false positive
38 not verified 85 CNVs confirmed
MLPA polulation study
1: present 
in normal population
84: absent
In general population
68: inherited 16: de novo
IPA  analysis
GO analysis
62 CNVs: unique 5 CNVs: each shared
by two patients
1 CNV: shared
by six patients
Genotype-phenotype correlation
MLPA polulation study
miR-Ontology
analysis
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 Figure 7: A typical MLPA Analysis performed in the general 
population and carried out on 4/123 CNVs identified by our study 
(see methods for explanations).  
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Table 1: Overview of the clinical features present in five out 
patients sharing a deletion on chromosome 15q11.2 
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Table 2: significant IPA ontologies associated to the genes 
regulated by the has-miR-150 
Function Annotation B-H p-value Molecules # Molecules 
absence seizure 4,86E-02 GABRG2 1 
purkinje cell degeneration 4,24E-02 CACNA1G 1 
neurological disorder 1,27E-02 
CACNA1G, COL4A4 
(includes EG:1286), 
EGR2, FZD4, GABRG2, 
GLDC, GLP1R, 
PAFAH1B1, PAK1, 
PPARGC1A, SLC2A4 11 
ossification of bone 1,27E-02 CALCR, EGR2 2 
developmental process of 
bone 1,45E-02 CALCR, EGR2, GLP1R 3 
resorption of bone 1,66E-02 CALCR, GLP1R 2 
differentiation of connective 
tissue cells 1,83E-02 
CALCR, PPARGC1A, 
SLC2A4 3 
mass of connective tissue 2,17E-02 CALCR, SLC2A4 2 
Alport's syndrome 2,10E-02 
COL4A4 (includes 
EG:1286) 1 
strength of neuromuscular 
junctions 1,45E-02 
COL4A4 (includes 
EG:1286) 1 
apoptosis of Schwann cells 2,87E-02 EGR2 1 
Charcot-Marie-Tooth disease 4,16E-02 EGR2 1 
congenital hypomyelination 1,60E-02 EGR2 1 
Dejerine-Sottas disease 1,67E-02 EGR2 1 
development of motor 
nucleus of trigeminal nerve 1,27E-02 EGR2 1 
development of peripheral 
nervous system 4,86E-02 EGR2 1 
development of rhombomere 
3 1,67E-02 EGR2 1 
development of rhombomere 
5 1,45E-02 EGR2 1 
development of rhombomere 
6 1,27E-02 EGR2 1 
development of trigeminal 
motor neurons 1,27E-02 EGR2 1 
differentiation of Schwann 
cells 3,11E-02 EGR2 1 
formation of rhombomere 3 1,27E-02 EGR2 1 
formation of rhombomere 5 1,27E-02 EGR2 1 
fusion of cranial nerve 
ganglion 1,45E-02 EGR2 1 
fusion of cranial nerve 
ganglion 1,45E-02 EGR2 1 
guidance of motor axons 3,35E-02 EGR2 1 
misrouting of axons 1,45E-02 EGR2 1 
myelination of neurons 2,38E-02 EGR2 1 
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myelination of peripheral 
nerve 1,45E-02 EGR2 1 
proliferation of Schwann cells 3,47E-02 EGR2 1 
quantity of motor neurons 4,90E-02 EGR2 1 
differentiation of neuroglia 1,67E-02 EGR2, NOTCH3 2 
development of brain 1,45E-02 
EGR2, NOTCH3, 
PAFAH1B1 3 
deafness of mice 2,99E-02 FZD4 1 
degeneration of cerebellum 2,38E-02 FZD4 1 
development of ear 3,11E-02 FZD4 1 
formation of body axis 2,71E-02 FZD4 1 
binding of hippocampus 1,45E-02 GABRG2 1 
childhood absence epilepsy 1,67E-02 GABRG2 1 
childhood absence epilepsy 1,67E-02 GABRG2 1 
fear response by mice 3,35E-02 GABRG2 1 
generalized epilepsy with 
febrile seizures plus 1,67E-02 GABRG2 1 
generalized tonic-clonic 
seizure 4,90E-02 GABRG2 1 
hyperpolarization 4,55E-02 GABRG2 1 
idiopathic generalized 
epilepsy 2,20E-02 GABRG2 1 
myoclonic seizure 3,60E-02 GABRG2 1 
panic-like anxiety 3,35E-02 GABRG2 1 
status epilepticus 3,71E-02 GABRG2 1 
Parkinson's disease 4,86E-02 
GABRG2, GLP1R, 
PAK1 3 
glycine encephalopathy 1,60E-02 GLDC 1 
fragility of bone 1,45E-02 GLP1R 1 
osteopenia of tibia 1,60E-02 GLP1R 1 
vasodilation of artery 4,90E-02 GLP1R 1 
learning 2,37E-02 GLP1R, PAFAH1B1 2 
locomotion 4,86E-02 GLP1R, PAFAH1B1 2 
disease of connective tissue 1,45E-02 GLP1R, PPARGC1A 2 
movement of mice 2,91E-02 GLP1R, PPARGC1A 2 
cadasil 1,45E-02 NOTCH3 1 
commitment of neurons 4,67E-02 NOTCH3 1 
differentiation of neuronal 
progenitor cells 3,75E-02 NOTCH3 1 
neurogenesis 2,91E-02 
NOTCH3, PAFAH1B1, 
PAK1 3 
cell division of neuronal 
progenitor cells 1,45E-02 PAFAH1B1 1 
disorganization of cortical 
subplate 1,27E-02 PAFAH1B1 1 
ectopia of neurons 1,67E-02 PAFAH1B1 1 
elongation of axons 4,67E-02 PAFAH1B1 1 
excitation of collateral 
synapses 1,27E-02 PAFAH1B1 1 
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hydrocephalus of mice 4,24E-02 PAFAH1B1 1 
hypertrophy of dentate 
granule cells 1,27E-02 PAFAH1B1 1 
length of pyramidal neurons 1,27E-02 PAFAH1B1 1 
lissencephaly 1,97E-02 PAFAH1B1 1 
migration of neural precursor 
cells 2,20E-02 PAFAH1B1 1 
morphogenesis of brain 2,20E-02 PAFAH1B1 1 
morphology of dentate 
granule cells 1,45E-02 PAFAH1B1 1 
positioning of cortical 
neurons 1,45E-02 PAFAH1B1 1 
scattering of neurons 1,83E-02 PAFAH1B1 1 
stratification of cerebral 
cortex 1,60E-02 PAFAH1B1 1 
stratification of hippocampus 1,45E-02 PAFAH1B1 1 
stratification of hippocampus 1,45E-02 PAFAH1B1 1 
thickness of ventricular zone 1,45E-02 PAFAH1B1 1 
transmigration of neurons 1,27E-02 PAFAH1B1 1 
transmission of synapse 3,23E-02 PAFAH1B1 1 
cell death of neurons 2,77E-02 
PAFAH1B1, PAK1, 
PPARGC1A 3 
disease of neurons 1,67E-02 
PAFAH1B1, 
PPARGC1A 2 
development of dendritic 
spines 2,99E-02 PAK1 1 
development of dendritic 
spines 2,99E-02 PAK1 1 
development of 
neuromuscular junctions 4,30E-02 PAK1 1 
growth of dendrites 4,30E-02 PAK1 1 
initiation of formation of 
dendrites 1,27E-02 PAK1 1 
cell death of cerebral cortex 
cells 3,11E-02 PAK1, PPARGC1A 2 
cell death of striatal neurons 1,27E-02 PAK1, PPARGC1A 2 
apoptosis of CA1 neuron 1,60E-02 PPARGC1A 1 
atrophy of neurons 3,23E-02 PPARGC1A 1 
cell death of dopaminergic 
neurons 4,90E-02 PPARGC1A 1 
cell death of neuronal 
progenitor cells 1,83E-02 PPARGC1A 1 
damage of brain 4,86E-02 PPARGC1A 1 
damage of hippocampal cells 2,20E-02 PPARGC1A 1 
damage of pyramidal neurons 1,83E-02 PPARGC1A 1 
degeneration of striatal 
neurons 2,20E-02 PPARGC1A 1 
hyperactive behavior of mice 3,75E-02 PPARGC1A 1 
hyperactivity of mice 2,55E-02 PPARGC1A 1 
neurodegeneration of striatal 1,83E-02 PPARGC1A 1 
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neurons 
neurological disorder of 
central nervous system 3,47E-02 PPARGC1A 1 
neurological disorder of 
striatum 1,97E-02 PPARGC1A 1 
organismal abnormalities of 
connective tissue 2,20E-02 PPARGC1A 1 
volume of neurons 1,60E-02 PPARGC1A 1 
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